Clinical implications of basic research in hepatocellular carcinoma

Journal of Hepatology

Volumn 64, Issue 3, 2016, Pages 736-745

  Dhanasekaran, Renumathy ^a   Venkatesh, Sudhakar K ^b   Torbenson, Michael S ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

Basic research; Clinical; HCC

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CANCER VACCINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NIVOLUMAB; SCATTER FACTOR RECEPTOR; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; TARGET OF RAPAMYCIN KINASE;

BASIC RESEARCH; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER THERAPY; HUMAN; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CASE REPORT; FEMALE; IMMUNOTHERAPY; LIVER NEOPLASMS; MEDICAL RESEARCH; MIDDLE AGED; PATHOLOGY;

ANGIOGENESIS INHIBITORS; BIOMEDICAL RESEARCH; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; TOR SERINE-THREONINE KINASES;

EID: 84958833214     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.09.008     Document Type: Review

References (83)

1. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, and et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 2015 E359 E386
2. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, and et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
3. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, J.S. Kim, and et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
4. A.L. Cheng, Y.K. Kang, D.Y. Lin, J.W. Park, M. Kudo, S. Qin, and et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial J Clin Oncol 31 2013 4067 4075
5. J.M. Llovet, T. Decaens, J.L. Raoul, E. Boucher, M. Kudo, C. Chang, and et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study J Clin Oncol 31 2013 3509 3516
6. A.X. Zhu, M. Kudo, E. Assenat, S. Cattan, Y.K. Kang, H.Y. Lim, and et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial JAMA 312 2014 57 67
7. R.P. Graham, L. Jin, D.L. Knutson, S.M. Kloft-Nelson, P.T. Greipp, N. Waldburger, and et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma Mod Pathol 28 2015 822 829
8. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma Eur J Cancer 48 2012 599 641
9. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
10. B. Müllhaupt, F. Durand, T. Roskams, P. Dutkowski, and M. Heim Is tumor biopsy necessary? Liver Transpl 17 2011 S14 S25
11. A. Forner, R. Vilana, C. Ayuso, L. Bianchi, M. Sole, J.R. Ayuso, and et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 2008 97 104
12. S. Leoni, F. Piscaglia, R. Golfieri, V. Camaggi, G. Vidili, P. Pini, and et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria Am J Gastroenterol 105 2010 599 609
13. Y.J. Lee, J.M. Lee, J.S. Lee, H.Y. Lee, B.H. Park, Y.H. Kim, and et al. Hepatocellular Carcinoma: Diagnostic Performance of Multidetector CT and MR Imaging - A Systematic Review and Meta-Analysis Radiology 275 2015 97 109
14. W. Schima, R. Hammerstingl, C. Catalano, L. Marti-Bonmati, E.J. Rummeny, F.T. Montero, and et al. Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: effect of contrast material flow rate AJR Am J Roentgenol 186 2006 1571 1579
15. K. Jhaveri, S. Cleary, P. Audet, F. Balaa, D. Bhayana, K. Burak, and et al. Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid) Am J Roentgenol 204 2015 498 509
16. J.M. Lee, and B.I. Choi Hepatocellular nodules in liver cirrhosis: MR evaluation Abdom Imaging 36 2011 282 289
17. J.W. Choi, J.M. Lee, S.J. Kim, J.H. Yoon, J.H. Baek, J.K. Han, and et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker Radiology 267 2013 776 786
18. M. Danila, I. Sporea, R. Sirli, A. Popescu, M. Sendroiu, and A. Martie The role of contrast enhanced ultrasound (CEUS) in the assessment of liver nodules in patients with cirrhosis Med Ultrasonography 12 2010 145 149
19. M. Claudon, C.F. Dietrich, B.I. Choi, D.O. Cosgrove, M. Kudo, C.P. Nolsoe, and et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS Ultrasound Med Biol 39 2013 187 210
20. J. Arita, K. Hasegawa, M. Takahashi, S. Hata, J. Shindoh, Y. Sugawara, and et al. Correlation between contrast-enhanced intraoperative ultrasound using Sonazoid and histologic grade of resected hepatocellular carcinoma AJR Am J Roentgenol 196 2011 1314 1321
21. J.F. Xu, H.Y. Liu, Y. Shi, Z.H. Wei, and Y. Wu Evaluation of hepatocellular carcinoma by contrast-enhanced sonography: correlation with pathologic differentiation J Ultrasound Med 30 2011 625 633
22. S. Chang, S.H. Kim, H.K. Lim, W.J. Lee, D. Choi, and J.H. Lim Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT AJR Am J Roentgenol 185 2005 400 405
23. M.A. Silva, B. Hegab, C. Hyde, B. Guo, J.A. Buckels, and D.F. Mirza Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis Gut 57 2008 1592 1596
24. M. Torbenson, and P. Schirmacher Liver cancer biopsy - Back to the future?! Hepatology 61 2015 431 433
25. M. Sherman, and J. Bruix Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice Hepatology 61 2015 433 436
26. J.L. Parker, N. Lushina, P.S. Bal, T. Petrella, R. Dent, and G. Lopes Impact of biomarkers on clinical trial risk in breast cancer Breast Cancer Res Treat 136 2012 179 185
27. A. Falconi, G. Lopes, and J.L. Parker Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer J Thorac Oncol 9 2014 163 169
28. A. Santoro, L. Rimassa, I. Borbath, B. Daniele, S. Salvagni, J.L. Van Laethem, and et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Lancet Oncol 14 2013 55 63
29. A. Vitale, E. Saracino, P. Boccagni, A. Brolese, F. D'Amico, E. Gringeri, and et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients Transplant Proc 41 2009 1260 1263
30. U. Cillo, A. Vitale, F. Grigoletto, F. Farinati, A. Brolese, G. Zanus, and et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system J Hepatol 44 2006 723 731
31. B.K. Kim, S.U. Kim, J.Y. Park, D.Y. Kim, S.H. Ahn, M.S. Park, and et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma Liver Int 32 2012 1120 1127
32. J.A. Marrero, R.J. Fontana, A. Barrat, F. Askari, H.S. Conjeevaram, G.L. Su, and et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort Hepatology 41 2005 707 715
33. J.S. Lee, I.S. Chu, J. Heo, D.F. Calvisi, Z. Sun, T. Roskams, and et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling Hepatology 40 2004 667 676
34. J.S. Lee, J. Heo, L. Libbrecht, I.S. Chu, P. Kaposi-Novak, D.F. Calvisi, and et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells Nat Med 12 2006 410 416
35. Y. Hoshida, S.M. Nijman, M. Kobayashi, J.A. Chan, J.P. Brunet, D.Y. Chiang, and et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Cancer Res 69 2009 7385 7392
36. P. Laurent-Puig, P. Legoix, O. Bluteau, J. Belghiti, D. Franco, F. Binot, and et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis Gastroenterology 120 2001 1763 1773
37. P. Kaposi-Novak, J.S. Lee, L. Gomez-Quiroz, C. Coulouarn, V.M. Factor, and S.S. Thorgeirsson Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J Clin Invest 116 2006 1582 1595
38. C. Coulouarn, V.M. Factor, and S.S. Thorgeirsson Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer Hepatology 47 2008 2059 2067
39. H. van Malenstein, O. Gevaert, L. Libbrecht, A. Daemen, J. Allemeersch, F. Nevens, and et al. A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma Clin Cancer Res 16 2010 4278 4288
40. A. Fujimoto, M. Furuta, Y. Shiraishi, K. Gotoh, Y. Kawakami, K. Arihiro, and et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity Nat Commun 6 2015 6120
41. J.C. Nault, A. De Reynies, A. Villanueva, J. Calderaro, S. Rebouissou, G. Couchy, and et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection Gastroenterology 145 2013 176 187
42. C.T. Lin, K.F. Hsu, T.W. Chen, J.C. Yu, D.C. Chan, C.Y. Yu, and et al. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg 34 2010 2155 2161
43. L. Yin, H. Li, A.-J. Li, W.Y. Lau, Pan. Z-y, E.C.H. Lai, and et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT J Hepatol 61 2014 82 88
44. F.Y. Yao, L. Ferrell, N.M. Bass, J.J. Watson, P. Bacchetti, A. Venook, and et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival Hepatology 33 2001 1394 1403
45. L. Bolondi, A. Burroughs, J.F. Dufour, P.R. Galle, V. Mazzaferro, F. Piscaglia, and et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions Semin Liver Dis 32 2012 348 359
46. T. Arao, K. Ueshima, K. Matsumoto, T. Nagai, H. Kimura, S. Hagiwara, and et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma Hepatology 57 2013 1407 1415
47. E. Horwitz, I. Stein, M. Andreozzi, J. Nemeth, A. Shoham, O. Pappo, and et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment Cancer Discov 4 2014 730 743
48. M. Scartozzi, L. Faloppi, G. Svegliati Baroni, C. Loretelli, F. Piscaglia, M. Iavarone, and et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study Int J Cancer 135 2014 1247 1256
49. F.V. Negri, B. Dal Bello, C. Porta, N. Campanini, S. Rossi, C. Tinelli, and et al. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment Liver Int 35 2015 2001 2008
50. M. Avila, and C. Berasain Making sorafenib irresistible. In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14 Hepatology 61 2015 1755 1757
51. C. Cainap, S. Qin, W.T. Huang, I.J. Chung, H. Pan, Y. Cheng, and et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial J Clin Oncol 33 2015 172 179
52. M.B. Thomas, J.S. Morris, R. Chadha, M. Iwasaki, H. Kaur, E. Lin, and et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma J Clin Oncol 27 2009 843 850
53. A.X.R.B. Zhu, C.J. Yen, M. Kudo, R.T.P. Poon, D. Pastorelli, J.F. Blanc, and et al. LBA16 - Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: Results from the randomized phase III REACH study Ann Oncol 25 2014 1 41
54. N.K. Venepalli, and L. Goff Targeting the HGF-cMET axis in hepatocellular carcinoma Int J Hepatol 2013 2013 341636
55. P. Kaposi-Novak, J.-S. Lee, L. Gòmez-Quiroz, C. Coulouarn, and et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J Clin Invest 116 2006 1582 1595
56. J.M. Llovet, C.E. Pena, C.D. Lathia, M. Shan, G. Meinhardt, and J. Bruix Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2290 2300
57. Verslype C, Cohn AL, Kelley RK, Yang TS, Su WC, Ramies DA, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). ASCO Meeting Abstracts 2012;30:4007.
58. O.V. Makarova-Rusher, J. Medina-Echeverz, A.G. Duffy, and T.F. Greten The yin and yang of evasion and immune activation in HCC J Hepatol 62 2015 1420 1429
59. A.G. Miamen, H. Dong, and L.R. Roberts Immunotherapeutic approaches to hepatocellular carcinoma treatment Liver Cancer 1 2012 226 237
60. L.A. Ormandy, T. Hillemann, H. Wedemeyer, M.P. Manns, T.F. Greten, and F. Korangy Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma Cancer Res 65 2005 2457 2464
61. J. Fu, D. Xu, Z. Liu, M. Shi, P. Zhao, B. Fu, and et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients Gastroenterology 132 2007 2328 2339
62. K. Wu, I. Kryczek, L. Chen, W. Zou, and T.H. Welling Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions Cancer Res 69 2009 8067 8075
63. S. Kalathil, A.A. Lugade, A. Miller, R. Iyer, and Y. Thanavala Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality Cancer Res 73 2013 2435 2444
64. E. Cariani, M. Pilli, A. Zerbini, C. Rota, A. Olivani, G. Pelosi, and et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma PLoS One 7 2012 e32493
65. E. Mizukoshi, Y. Nakamoto, K. Arai, T. Yamashita, A. Sakai, Y. Sakai, and et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma Hepatology 53 2011 1206 1216
66. K. Hiroishi, J. Eguchi, T. Baba, T. Shimazaki, S. Ishii, A. Hiraide, and et al. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma J Gastroenterol 45 2010 451 458
67. L.H. Butterfield, A. Ribas, V.B. Dissette, Y. Lee, J.Q. Yang, P. De la Rocha, and et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides Clin Cancer Res 12 2006 2817 2825
68. T.F. Greten, A. Forner, F. Korangy, G. N'Kontchou, N. Barget, C. Ayuso, and et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma BMC Cancer 10 2010 209
69. Y. Sawada, T. Yoshikawa, D. Nobuoka, H. Shirakawa, T. Kuronuma, Y. Motomura, and et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival Clin Cancer Res 18 2012 3686 3696
70. Y. Hong, Y. Peng, Z.S. Guo, J. Guevara-Patino, J. Pang, L.H. Butterfield, and et al. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma Hepatology 59 2014 1448 1458
71. K.M. Mahoney, G.J. Freeman, and D.F. McDermott The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma Clin Ther 37 2015 764 782
72. J.R. Brahmer, H. Hammers, and E.J. Lipson Nivolumab: targeting PD-1 to bolster antitumor immunity Future Oncol 11 2015 1307 1326
73. B. Sangro, C. Gomez-Martin, M. de la Mata, M. Inarrairaegui, E. Garralda, P. Barrera, and et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C J Hepatol 59 2013 81 88
74. El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015 (suppl; abstr LBA101).
75. J.C. Nault, M. Mallet, C. Pilati, J. Calderaro, P. Bioulac-Sage, C. Laurent, and et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions Nat Commun 4 2013 2218
76. A.A. Chiappori, T. Kolevska, D.R. Spigel, S. Hager, M. Rarick, S. Gadgeel, and et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer Ann Oncol 26 2015 354 362
77. J.E. Koziel, and B.S. Herbert The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells Breast Cancer Res Treat 149 2015 607 618
78. C. Guichard, G. Amaddeo, S. Imbeaud, Y. Ladeiro, L. Pelletier, I.B. Maad, and et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma Nat Genet 44 2012 694 698
79. W. Gao, Z. Tang, Y.-F. Zhang, M. Feng, M. Qian, D.S. Dimitrov, and et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis Nat Commun 6 2015 6536
80. G. Giannelli, E. Villa, and M. Lahn Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma Cancer Res 74 2014 1890 1894
81. A. Mazzocca, E. Fransvea, G. Lavezzari, S. Antonaci, and G. Giannelli Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation Hepatology 50 2009 1140 1151
82. Faivre S SA, Kelley RK, et al. A Phase 2 study of novel transforming growth factor-beta (TGF-β) receptor 1 kinase inhibitor, LY2157299 monohydrate in patients with advanced hepatocellular carcinoma (HCC). In: Presented at: 2014 Gastrointestinal Cancers Symposium; January 16-18, 2014; San Francisco, CA. - See more at: http://www.onclive.com/conference-coverage/gcs-2014/Novel-Targeted-Agent-Leads-to-Survival-Benefit-in-HCC - sthash.WYz42iCN.dpuf.
83. M.S. Brose, C.T. Frenette, S.M. Keefe, and S.M. Stein Management of sorafenib-related adverse events: a clinician's perspective Semin Oncol 41 2014 S1 S16